几个问题,如肌痛,关节痛,发烧,呼吸困难,全身性水肿,化疗后癌症患者会出现胸腔积液,特别是在第一次化疗的第一个周期。虽然假设一些细胞因子与这些症状和体征的发展有关,其病理生理学尚未完全发现。它们通常很温和,但他们可能很少进展到“系统性毛细血管渗漏综合征”的严重阶段,死亡率很高。这项研究的目的是探讨血清白细胞介素-2(IL-2)水平之间的关系,白细胞介素-11(IL-11),肿瘤坏死因子α(TNF-α),血管内皮生长因子(VEGF),以及这些症状和体征。共有44名既没有心脏的癌症患者,肺,肝脏,肾,或甲状腺疾病被纳入这项研究。在第一次化疗治疗的第一个周期之前和化疗后24小时检查并询问了他们的症状和体征。采集所有参与者的血清样本,和VEGF,TNF,研究了IL-2和IL-11水平。化疗药物之间没有关联,以及水肿等症状和体征,呼吸困难,咳嗽,和流感样症状。与接受紫杉醇治疗组相比,其他治疗组的IL-11水平显著下降,多西他赛,吉西他滨,化疗后第一天和长春瑞滨(P=.006)。然而,在症状和体征之间没有观察到任何关系,对化疗的反应,血清VEGF水平,TNF,IL-2和IL-11。这些症状和危及生命的综合征一直是临床医生之间的当前话题。尽管一些毒品和调解员被指控,其病理生理学尚未完全发现。在这项研究中,我们无法检测到症状之间的任何关联,标志,和化疗后的细胞因子水平。
Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of \"Systemic Capillary Leak Syndrome\" with a high mortality rate. The objective of this study was to investigate the association between the serum levels of interleukin-2 (IL-2), interleukin-11 (IL-11), tumor necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), and these symptoms and signs. A total of 44 cancer patients who had neither heart, lung, liver, renal, or thyroid disease were recruited into this study. Their symptoms and signs were examined and questioned before the first cycle of the first chemotherapy treatment and the 24 h after this chemotherapy. All participant\'s serum samples were taken, and the VEGF, TNF, IL-2, and IL-11 levels were studied. There was no association between the chemotherapeutic drugs, and the symptoms and signs such as edema, dyspnea, coughing, and flu-like symptoms. There was a significant decrease in IL-11 levels in the other treatment group compared with the group receiving paclitaxel, docetaxel, gemcitabine, and vinorelbine in the first day following chemotherapy (P = .006). However, no relation was observed between the symptoms and signs, the response to the chemotherapy, and the serum levels of VEGF, TNF, IL-2, and IL-11. These symptoms and life-threatening syndrome have been a current topic between the clinicians. Although some drugs and mediators are accused, its pathophysiology has not been discovered completely yet. In this study, we could not detect any association between the symptoms, signs, and the cytokine levels following the chemotherapy.